1. Merck Manual of Diagnosis. Merck Research Laboratories, Whitehouse Station, NY, 1999: 1838-1839.

 

2. Robbins et al. Pocket Guide to Robbins Pathologic Basis of Disease, 6^th Ed. WB Saunders Company, Philadelphia, PA 1999;493.

 

3. NIH Consensus Conference. Prevention and Treatment of Kidney Stones. JAMA 1988;260:977-981.

 

4. Handbook of Signs and Symptoms. Springhouse Corp, Spirnghouse, PA, 1998:62.

 

5. Merck Manual of Diagnosis. Merck Research Laboratories, Whitehouse Station, NY, 1999: 1840.

 

6. Curhan GC et al A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. New Engl J Med 1993;328:833-838.

 

7. Curhan GC et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk of kidney stones in women. Ann Intern Med 1997;126:497-504.

 

8. Goldfarb S. Dietary factors in the pathogenesis and prophylaxis of calcium nephrolithiais. Kidney Int 1988;34:544-555.

 

9. Curhan GC et al. A prospective study of the intake of Vitamins C and B6 and the risk of kidney stones in men. J urol 1996;155:1847-1851.

 

10. Levine et al. Effect of calcium citrate supplementation on urinary calcium oxalate saturation in female stone formers: Implications for prevention of osteoporosis. Am J Clin Nutr 1994;60:592-596.

 

11. Lyon ES et al. Calcium oxalate lithiasis produced by pyridoxine deficiency and inhibition with high magnesium diets. 1966;4:133.

 

12. Prien EL and Gurshoff SN. Magnesium oxide-pyridoxine therapy for recurrent calcium oxalate calculi. J Urol 1974;112:509-512

 

13. Thind SK et al. Role of Vitamin B6 in oxalate metabolism in urolithiais. Am J Clin Nutr 1979;32(6):xx(Abstract).

 

14. Murthy MSR et al. Effect of pyridoxine supplementation on recurrent stone formers. Int J Clin Pharmacol Ther Toxicol 1982;20:434.

 

15. Will EJ and Bijvoet OLM. Primary oxalosis: clinical and biochemical response to high dose pyridoxine therapy. Metabolism 1979;28:542.

 

16. Yendt ER and Cohanim M. Response to a physiologic dose of pyridoxine in primary hyperoxaluria (PH) Type 1. Urol Res 1984;12:27.

 

17. Milliner DS et al. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med 1994;331:1553-1558.

 

18. Johansson G et al. Biochemical and clinical effects of the prophylactic treatment of renal calcium stones with magnesium hydroxide. J Urol 1980;124:770.

 

19. Johansson G et al. Effects of magnesium hydroxide in renal stone disease. J Am Coll Nutr 1982;1:179-185.

 

20. Rattan V et al. Effect of combined supplementation of magnesium oxide and pyridoxine in calcium oxalate stone formers. Urol Res 1994;22:161-165.

 

21. Harvey et al. Calcium citrate: Reduced propensity for the crystallization of calcium oxalate in urine resulting form induced hypercalciuria of calcium supplementation. J  Endocrin Metab 1985;61:1223-1225.